CF101
Sponsors
Can-Fite BioPharma
Conditions
GlaucomaKeratoconjunctivitis SiccaOcular HypertensionOsteoarthritis of the KneePlaque PsoriasisRheumatoid ArthritisUveitis, IntermediateUveitis, Posterior
Phase 2
Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
CompletedNCT00280917
Start: 2006-06-30End: 2007-04-30Updated: 2023-09-18
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
CompletedNCT00349466
Start: 2007-01-31End: 2009-05-31Updated: 2022-05-09
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
CompletedNCT00556894
Start: 2008-02-29End: 2009-04-30Updated: 2018-03-29
A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the Knee
WithdrawnNCT00837291
Start: 2018-11-30End: 2019-01-31Updated: 2018-02-01
Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular Pressure
CompletedNCT01033422
Start: 2010-10-31End: 2017-04-30Updated: 2022-05-12
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
CompletedNCT01034306
Start: 2010-10-31End: 2013-12-31Updated: 2022-05-24
Trial of CF101 to Treat Patients With Psoriasis
CompletedNCT01265667
Start: 2011-07-31End: 2015-05-31Updated: 2020-11-18
Safety &Efficacy of CF101 to Subjects With Uveitis
WithdrawnNCT01905124
Start: 2019-01-31End: 2019-10-31Updated: 2018-02-01